These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 25993227)

  • 1. Decision making in the context of breast cancer chemoprevention: patient perceptions and the meaning of risk.
    Holmberg C
    Am Soc Clin Oncol Educ Book; 2015; ():e59-64. PubMed ID: 25993227
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The selective estrogen receptor modulators in breast cancer prevention.
    Li F; Dou J; Wei L; Li S; Liu J
    Cancer Chemother Pharmacol; 2016 May; 77(5):895-903. PubMed ID: 26787504
    [TBL] [Abstract][Full Text] [Related]  

  • 3. NRG Oncology/National Surgical Adjuvant Breast and Bowel Project Decision-Making Project-1 Results: Decision Making in Breast Cancer Risk Reduction.
    Holmberg C; Bandos H; Fagerlin A; Bevers TB; Battaglia TA; Wickerham DL; McCaskill-Stevens WJ
    Cancer Prev Res (Phila); 2017 Nov; 10(11):625-634. PubMed ID: 28978566
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Benefits and harms of selective oestrogen receptor modulators (SERMs) to reduce breast cancer risk: a cross-sectional study of methods to communicate risk in primary care.
    McIntosh JG; Minshall J; Saya S; Bickerstaffe A; Hewabandu N; Qama A; Emery JD
    Br J Gen Pract; 2019 Dec; 69(689):e836-e842. PubMed ID: 31636127
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Women's preferences for selective estrogen reuptake modulators: an investigation using protection motivation theory.
    Ralph AF; Ager B; Bell ML; Collins IM; Andrews L; Tucker K; Phillips KA; Butow P
    Patient Educ Couns; 2014 Jul; 96(1):106-12. PubMed ID: 24856850
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Addressing barriers to uptake of breast cancer chemoprevention for patients and providers.
    Crew KD
    Am Soc Clin Oncol Educ Book; 2015; ():e50-8. PubMed ID: 25993215
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Breast Cancer Chemoprevention: A Practical Guide for the Primary Care Provider.
    Farkas A; Vanderberg R; Merriam S; DiNardo D
    J Womens Health (Larchmt); 2020 Jan; 29(1):46-56. PubMed ID: 31560601
    [TBL] [Abstract][Full Text] [Related]  

  • 8. What Factors Influence Decision-Making about Breast Cancer Chemoprevention among High-Risk Women?
    Crew KD
    Cancer Prev Res (Phila); 2017 Nov; 10(11):609-611. PubMed ID: 28978567
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Chemoprevention of breast cancer with selective estrogen receptor modulators: views from broadly diverse focus groups of women with elevated risk for breast cancer.
    Cyrus-David MS; Strom SS
    Psychooncology; 2001; 10(6):521-33. PubMed ID: 11747064
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Chemoprevention of breast cancer.
    Dalton RR; Kallab AM
    South Med J; 2001 Jan; 94(1):7-15. PubMed ID: 11213947
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Informed choice about breast cancer prevention: randomized controlled trial of an online decision aid intervention.
    Korfage IJ; Fuhrel-Forbis A; Ubel PA; Zikmund-Fisher BJ; Greene SM; McClure JB; Smith DM; Alford SH; Fagerlin A
    Breast Cancer Res; 2013; 15(5):R74. PubMed ID: 24004815
    [TBL] [Abstract][Full Text] [Related]  

  • 12. My Lived Experiences Are More Important Than Your Probabilities: The Role of Individualized Risk Estimates for Decision Making about Participation in the Study of Tamoxifen and Raloxifene (STAR).
    Holmberg C; Waters EA; Whitehouse K; Daly M; McCaskill-Stevens W
    Med Decis Making; 2015 Nov; 35(8):1010-22. PubMed ID: 26183166
    [TBL] [Abstract][Full Text] [Related]  

  • 13. SERMs in chemoprevention of breast cancer.
    Gasco M; Argusti A; Bonanni B; Decensi A
    Eur J Cancer; 2005 Sep; 41(13):1980-9. PubMed ID: 15964182
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Decision aids for breast cancer chemoprevention.
    Juraskova I; Bonner C
    Breast Cancer Res; 2013; 15(5):106. PubMed ID: 24050596
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Atypia in random periareolar fine-needle aspiration affects the decision of women at high risk to take tamoxifen for breast cancer chemoprevention.
    Goldenberg VK; Seewaldt VL; Scott V; Bean GR; Broadwater G; Fabian C; Kimler B; Zalles C; Lipkus IM
    Cancer Epidemiol Biomarkers Prev; 2007 May; 16(5):1032-4. PubMed ID: 17507634
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tamoxifen vs Raloxifene vs Exemestane for Chemoprevention.
    Reimers L; Crew KD
    Curr Breast Cancer Rep; 2012 Sep; 4(3):207-215. PubMed ID: 23956815
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Selective estrogen receptor modulators and postmenopausal health.
    Roe EB; Chiu KM; Arnaud CD
    Adv Intern Med; 2000; 45():259-78. PubMed ID: 10635051
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Chemoprevention of breast cancer: a hope justified?].
    Buser K; Delaloye JF
    Rev Med Suisse Romande; 2000 Jun; 120(6):511-3. PubMed ID: 11014095
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prevention of hormone-related cancers: breast cancer.
    Dunn BK; Wickerham DL; Ford LG
    J Clin Oncol; 2005 Jan; 23(2):357-67. PubMed ID: 15637398
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Breast Cancer Chemoprevention among High-risk Women and those with Ductal Carcinoma In Situ.
    Reimers LL; Sivasubramanian PS; Hershman D; Terry MB; Greenlee H; Campbell J; Kalinsky K; Maurer M; Jayasena R; Sandoval R; Alvarez M; Crew KD
    Breast J; 2015; 21(4):377-86. PubMed ID: 25879521
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.